Fennec Provides Business Update And Reports Third Quarter 2017 Results

During the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study  Study met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing loss without any evidence of tumor protection in patients with Standard Risk Hepatoblastoma (SR-HB) Company plans to pursue regulatory approvals with FDA and EU in 2018 […]

Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting

Study met primary endpoint (p=0.0033) Significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with Standard Risk Hepatoblastoma (SR-HB) Company plans to pursue regulatory approvals with FDA and EMA RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2017 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused […]

FENNEC TO PRESENT AT THE CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE ON SEPTEMBER 27, 2017 IN NEW YORK CITY

Research Triangle Park, NC, September 20, 2017 – Fennec Pharmaceuticals, Inc. (NASDAQ: FENC, TSX: FRX), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the Cantor Fitzgerald Global Healthcare Conference in New York on September 27 at 4:00 pm. Management will also be available to meet with investors during the conference. The […]

Fennec Announces Preliminary Results of SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) to be Presented at the 49TH Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting

SIOPEL 6 shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumor protection Among the first 94 evaluable patients, hearing loss occurred in 29/44=65.9% under Cisplatin Arm and in 19/50=38.0% under Cis+STS Arm, corresponding to a relative risk of 0.57 (P=0.0069) Late Breaker Oral Presentation […]

Fennec Pharmaceuticals Announces Listing on the Nasdaq Capital Market

Trading on Nasdaq under the symbol “FENC” is expected to commence on September 13, 2017 RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2017 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (TSX:FRX), (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that its […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES SECOND QUARTER 2017 RESULTS

– SIOPEL 6 Results expected Q4 2017 – $7.6 million financing led by VENBIO Select Advisor in June 2017 RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – Aug. 11, 2017) – Fennec Pharmaceuticals Inc. (TSX:FRX) (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported […]

FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING

Research Triangle Park, NC — (Marketwired) – June 28, 2017– Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated May 19, 2017(the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and Special […]

FENNEC ANNOUNCES $7.6 MILLION PRIVATE PLACEMENT OF COMMON SHARES LED BY VENBIO SELECT ADVISOR

Research Triangle Park, NC, June 8, 2017 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) (the “Company” or “Fennec”), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it has completed a non-brokered private placement (the “Offering”) of 1,900,000 […]

FENNEC ANNOUNCES LAUNCH OF EUROPEAN NAMED PATIENT PROGRAMME FOR SODIUM THIOSULFATE FOR PEDIATRIC PATIENTS WITH STANDARD RISK HEPATOBLASTOMA

Research Triangle Park, NC, May 30, 2017 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced the launch of a Named Patient Programme (NPP) in Europe for STS. Fennec’s NPP is intended to […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES FIRST QUARTER 2017 RESULTS

Research Triangle Park, NC, May 12, 2017 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the first quarter ended March 31, 2017. Upcoming Events for […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2016 FINANCIAL RESULTS

Research Triangle Park, NC, March 30, 2017 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for  the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2016. “We are pleased with […]